A strong relation between dose and mortality was seen (p=0.003), especially at >300 mg/day.
The greatest mortality was seen if the POSSUM score was over 42 (P = 0.0092, Table 4).
Best prediction of 28-day mortality was seen in GC (AUROC 0.64, p < 0.005), as illustrated in Fig. 2.
No mortality was seen in any treatment group after CMC or saline infusion.
Some increment in mortality was seen in the recent cohort (14 deaths/166 PYO = 8.4 per 100 PYO).
After challenge, protection from morbidity and mortality was seen in mice and ferrets, with significant reductions in viral shedding and disease progression seen in vaccinated animals.
In 2005, little mortality was seen below 8°C-weeks of thermal stress while above it there was an ecologically important 1-in-3 risk of mortality.
No initial treatment-related mortality was seen in the rats.
Significantly increased mortality was seen with lower income among Filipinos.
Adjusted mortality was seen to decrease over the study period.
Increasing mortality was seen with age, APACHE II score and delay in initiation of RRT.
